Menu
Request a demo

Our products

An agile launch execution platform, with full visibility across countries and functions.
A collaborative platform for teams who plan reimbursements and HTA activities.
A collaborative platform designed to manage pharmaceutical tenders across countries.
A capability management platform that unifies capabilities, resources, and assessment.
Manage your entire pipeline. Track every move. Stay ahead, from discovery to launch.

Our expertise

Launch Readiness

Market Access

Tender Management

Featured Post

6 Pharma Trends for 2025: Trump’s Return, AI Breakthroughs, and Market Access Challenges

  • Andre Moa
  • 21 Jan 2025
  • 21 minute read

Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.

Read more

Latest posts

Launch Readiness 2025: What this year holds in store for pharma product launches

Pharma innovation stays strong, but market access barriers persist. Discover key trends and strategies in our Launch Readiness 2025 report.

Read more

6 Pharma Trends for 2025: Trump’s Return, AI Breakthroughs, and Market Access Challenges

Discover 6 key pharma trends for 2025, including Trump's policies, AI-driven innovations, market access challenges, and evolving global regulations shaping the industry.

Read more

2024 New Drug Approvals: Key FDA and EMA approvals, breakthroughs and market trends

Discover key FDA & EMA drug approvals of 2024, breakthrough innovations, and market trends. Explore what these approvals reveal about the pharma industry's future.

Read more

Market Access 2025: Navigating the emerging HTA and drug reimbursement challenges

Discover insights from 'Market Access 2025' on overcoming HTA and drug reimbursement challenges. Learn strategies to navigate evolving market access hurdles.

Read more

Launch Readiness 2024: A fresh look at key trends affecting pharma product launches

Revitalized US approvals and thriving innovation are positive signs for new medicines this year. However, our Launch Readiness 2024 guide shows that cost and value remain critical to launch success.

Read more

3 Pharma Trends for 2024: All about market access

Discover the key HTA and market access challenges in the pharma industry for 2024 and how companies can navigate them. Learn about the impact of EU's pharma review and price pressures in Germany and Japan, and get ready for EU's HTAR.

Read more

2023 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations

2023 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations

Read more

Market Access 2023: New Report on key challenges in HTA and reimbursement

As market access barriers proliferate, digitally enabled alignment is key to optimising new drug uptake.

Read more

Launch Readiness 2023: Key trends impacting pharma product launches

Our Launch Readiness 2023 report examines the prospects and challenges for new medicines entering the market in the shadow of COVID-19.

Read more

5 Pharma Trends for 2023: Challenges and opportunities in the post-COVID landscape

Pharma is facing a new set of launch, market access and strategic challenges as the pandemic has changed some market characteristics for good.

Read more

2022 New Drug Approvals: Review of New FDA and EMA Marketing Authorisations

We look at how EU drug approvals hold firm in 2022, US lags and innovation flourishes

Read more

New Report: Launch Readiness 2022 - How to address key trends and challenges

With COVID-19 driving innovation and agility, 2022 promises another rich crop of pharma launches. Closer cost-benefit scrutiny demands carefully differentiated value.

Read more

Recent Posts

Most Popular Posts

Categories

Get our latest
posts in your inbox

TRiBECA Knowledge needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Notice.